Last updated: September 7, 2026
Vivotif is a live oral typhoid vaccine containing the attenuated Salmonella Typhi strain Ty21a. Its commercial position is supported by established regulatory approvals, a differentiated four-dose oral regimen and demand from international travel. The product does not have the financial disclosure profile of a large biologic medicine: Bavarian Nordic reports Vivotif within broader travel-health results and does not publish audited standalone revenue for the brand.
The principal commercial risks are travel-volume volatility, competition from injectable and conjugate typhoid vaccines, the need for patient adherence to a four-dose schedule and limited relevance outside travel medicine and endemic-market vaccination programs. The principal intellectual-property risk is low relative to newly launched biologics because the original Ty21a technology is mature and Vivotif does not appear to depend on a significant remaining composition-of-matter patent estate.
What is Vivotif and how is it used?
Vivotif is an oral live attenuated vaccine for active immunization against typhoid fever caused by Salmonella Typhi. In the United States, the product is supplied as delayed-release capsules and is administered as four doses on days 0, 2, 4 and 6. The full course should be completed at least one week before potential exposure. Revaccination is generally recommended every five years for persons who remain at risk, according to the U.S. prescribing information [1].
| Attribute |
Vivotif profile |
| Active biological agent |
Live attenuated Salmonella Typhi Ty21a |
| Dosage form |
Delayed-release oral capsule |
| U.S. indication |
Active immunization against typhoid fever |
| Standard adult schedule |
Four capsules on alternate days |
| Administration requirement |
Swallow with cool or lukewarm water; avoid hot beverages |
| Booster interval |
Generally five years for continued-risk individuals |
| Product category |
Travel vaccine and biologic vaccine |
| U.S. regulatory authority |
FDA Center for Biologics Evaluation and Research |
| Primary commercial use |
International travelers |
| Manufacturer/owner |
Bavarian Nordic following acquisition of the travel-health business from Emergent BioSolutions |
Vivotif is not a routine U.S. childhood vaccine. The CDC recommends typhoid vaccination for travelers to areas where typhoid fever is common, particularly where exposure to contaminated food and water is likely. Vaccination does not replace food and water precautions [2].
Who owns Vivotif and how has its commercial position changed?
Bavarian Nordic acquired Vivotif and Vaxchora from Emergent BioSolutions in 2023 in a transaction valued at approximately $270 million. The acquisition expanded Bavarian Nordic’s travel-vaccine portfolio and reduced its dependence on a smaller number of flagship products [3].
The transaction changed Vivotif’s commercial context in three ways:
- Vivotif became part of a dedicated travel-health portfolio that includes products with related prescriber, distributor and travel-clinic channels.
- Bavarian Nordic obtained cross-selling opportunities with Vaxchora, the oral cholera vaccine.
- The product gained access to a company whose commercial strategy is centered on vaccines rather than a broader emergency-response and contract-manufacturing portfolio.
The acquired products also give Bavarian Nordic exposure to travel recovery. That exposure is commercially attractive during periods of rising international travel, but it creates substantial seasonality and sensitivity to travel restrictions, airline capacity, consumer confidence and geopolitical events.
What is Vivotif’s financial trajectory?
Vivotif’s standalone revenue is not publicly disclosed in Bavarian Nordic’s reported financial statements. The company reports performance by broader business areas, including travel-health activities, rather than publishing a separate audited revenue line for Vivotif. Any precise current estimate of Vivotif revenue would therefore be an external market estimate, not company-reported financial data.
The likely financial trajectory is best understood through operating drivers:
| Period |
Financial driver |
Expected effect on Vivotif |
| 2020-2021 |
International travel disruption |
Sharp demand pressure |
| 2022-2023 |
Travel-market reopening |
Recovery in prescriptions and travel-clinic demand |
| 2023 onward |
Bavarian Nordic ownership |
Portfolio integration and channel expansion |
| Current commercial phase |
Normalized travel demand |
More stable base demand, with seasonal peaks |
| Longer term |
Competition from injectable and conjugate vaccines |
Pressure on share and pricing in selected markets |
Vivotif has characteristics of a mature specialty vaccine rather than a high-growth biologic:
- Demand is linked to travel volume rather than chronic treatment prevalence.
- Prescriptions are concentrated before major travel seasons.
- Revenue is distributed across travel clinics, pharmacies, occupational-health providers and public-health channels.
- Pricing is influenced by private-pay status in many travel markets.
- Unit growth depends on international mobility and clinical recommendations.
- Manufacturing continuity and cold-chain execution are important because supply interruptions can affect seasonal sales.
Bavarian Nordic’s acquisition price provides a reference point for the strategic value assigned to the travel-health assets, but it does not establish a Vivotif valuation. The transaction included Vaxchora and related commercial rights, so the consideration cannot be allocated reliably to Vivotif alone.
How does Vivotif compare with competing typhoid vaccines?
Vivotif competes with injectable Vi polysaccharide vaccines and typhoid conjugate vaccines. The products differ materially in age eligibility, schedule, duration of protection, procurement channels and suitability for mass vaccination.
| Vaccine category |
Administration |
Main commercial strength |
Main limitation |
| Vivotif |
Four-dose oral course |
Needle-free administration and established travel use |
Adherence, live-vaccine restrictions and cold-chain requirements |
| Vi polysaccharide vaccine |
Single injection |
Simple schedule and broad travel-clinic familiarity |
Booster usually required after approximately two years |
| Typhoid conjugate vaccine |
Single injection |
Longer protection and suitability for younger children and public programs |
Primarily positioned in endemic-market and public-health settings |
Typhoid conjugate vaccines, including Typbar-TCV and comparable products, have strengthened competition in endemic countries. The World Health Organization recommends typhoid conjugate vaccines for children from six months of age in typhoid-endemic areas and in settings with antimicrobial resistance concerns [4].
Vivotif retains a distinct position among adult travelers who prefer an oral vaccine and can complete the schedule. Its competitive position is weaker when a health system prioritizes a single-dose product, mass immunization, pediatric use or high coverage with minimal adherence requirements.
What FDA regulatory status does Vivotif have?
Vivotif is an FDA-approved live oral typhoid vaccine. It is regulated as a biological product, and its prescribing information identifies the vaccine strain, dosing schedule, storage requirements, contraindications and drug-interaction restrictions [1].
The product is not appropriate for everyone. The FDA label includes restrictions involving acute febrile illness, immunocompromising conditions and concurrent antibacterial therapy. Antibiotics can interfere with replication of the live vaccine strain. The label also requires refrigerated storage, which increases distribution and inventory-management requirements.
Vivotif is not part of the standard U.S. routine immunization schedule. Its demand is generated primarily by individual risk assessment before international travel.
Does Vivotif have FDA exclusivity?
Vivotif does not have the profile of a recently approved biologic with remaining reference-product exclusivity. Its commercial protection derives mainly from brand recognition, regulatory history, manufacturing capability, distribution and clinical familiarity.
No major current FDA biologic exclusivity event is publicly associated with Vivotif comparable to the 12-year reference-product exclusivity framework used for newer biologics. The product’s mature regulatory history reduces the probability that exclusivity expiration will produce a sudden loss of market access.
What patents protect Vivotif?
The original Ty21a vaccine technology is decades old. The key commercial protection is unlikely to be a current composition-of-matter patent covering the underlying attenuated strain. Any original patents associated with Ty21a development would generally have expired by now.
The remaining protection is more likely to involve:
- Manufacturing know-how for maintaining vaccine potency and genetic stability.
- Fermentation and stabilization processes.
- Capsule formulation and delayed-release performance.
- Quality-control methods.
- Trade secrets related to seed lots, production conditions and release testing.
- Regulatory approvals and accumulated safety data.
A definitive current patent-family analysis would require a live review of international patent registers and assignments. Publicly available commercial information does not indicate that Vivotif depends on a high-value, late-expiring patent blocking generic or biosimilar competition.
What is the Orange Book status of Vivotif?
The Orange Book is not the primary reference for Vivotif’s regulatory protection because Vivotif is a biologic vaccine regulated through FDA biologics pathways. The Purple Book is the more relevant FDA resource for licensed biological products and biosimilar-related reference-product information [5].
Vivotif is therefore unlikely to generate the conventional Orange Book patent-certification process associated with small-molecule products. A Paragraph IV challenge is not the principal expected pathway for a competitor seeking to commercialize a comparable typhoid vaccine.
Are there Paragraph IV challenges or biosimilar risks for Vivotif?
No prominent public Paragraph IV litigation or biosimilar challenge targeting Vivotif is identified in the available commercial record. The more relevant competitive risk is a competing vaccine approved through an independent biological-product pathway rather than a direct generic substitution.
A follow-on developer would face several barriers:
- Demonstrating consistent biological identity and potency.
- Establishing manufacturing comparability or clinical effectiveness.
- Securing suitable live-strain production capability.
- Meeting cold-chain and stability requirements.
- Building physician, travel-clinic and distributor acceptance.
- Competing against established injectable and conjugate products.
A biosimilar-style pathway is technically less straightforward for a live attenuated oral vaccine than for a well-characterized monoclonal antibody. A competitor could instead pursue an independent vaccine approval, but that route would require substantial development, clinical and manufacturing investment.
What formulation and manufacturing barriers protect Vivotif?
Vivotif’s delayed-release capsule is commercially important because the vaccine strain must survive passage through the stomach and reach the intestine. The product also requires controlled storage and handling.
Manufacturing barriers include:
- Maintenance of the Ty21a seed system and genetic characteristics.
- Consistent fermentation and biological yield.
- Potency testing for a live attenuated organism.
- Stability of the finished capsule under refrigerated conditions.
- Control of contamination and batch variability.
- Validation of release assays and microbiological testing.
These barriers do not create the same level of exclusion as a strong patent estate. They can, however, delay market entry and increase the cost of competing products. For a relatively specialized travel-vaccine market, the required investment may be difficult to justify without a broader typhoid or travel-health portfolio.
What litigation and settlement agreements affect Vivotif?
No material current patent litigation or major generic settlement agreement involving Vivotif is identified in the available public record. The absence of a high-profile patent dispute is consistent with a mature product whose primary competitive barriers are regulatory, manufacturing and commercial rather than patent-based.
Litigation risk could still arise from product liability, labeling, manufacturing quality, supply contracts or competition-law issues. Those risks are separate from the conventional Hatch-Waxman litigation model used for small-molecule drugs.
What geographic markets drive Vivotif sales?
Vivotif has the strongest strategic relevance in countries with established travel-medicine systems and substantial outbound travel. These markets include the United States, parts of Europe and other high-income countries where travelers routinely purchase vaccines before visiting typhoid-endemic regions.
Geographic demand is shaped by:
- International travel from high-income countries.
- Travel-clinic density.
- Private reimbursement and out-of-pocket purchasing.
- National travel-vaccine recommendations.
- Distribution access through pharmacies and clinics.
- Typhoid incidence and antimicrobial resistance in destination countries.
In endemic countries, typhoid conjugate vaccines have a stronger strategic position because they are suitable for pediatric programs and public procurement. Vivotif’s oral four-dose schedule is less suited to mass campaigns that prioritize one-visit coverage.
How strong is Vivotif’s commercial and patent estate?
Vivotif has a moderate commercial position and a limited apparent patent moat.
| Factor |
Assessment |
| Brand and clinical familiarity |
Moderate to strong in travel medicine |
| Regulatory durability |
Strong, based on long market history |
| Patent exclusivity |
Limited or low based on product age |
| Manufacturing complexity |
Moderate to high |
| Substitution risk |
Moderate |
| Biosimilar risk |
Low near term |
| Generic-style substitution risk |
Low to moderate |
| Travel-cycle exposure |
High |
| Pricing power |
Moderate in private-pay travel channels |
| Geographic expansion potential |
Moderate, but weaker in endemic public markets |
The most defensible assets are the approved product, manufacturing system, distribution network and established position with travel-health professionals. The estate is less protected by a single patent than by the difficulty of reproducing a live oral vaccine economically at commercial scale.
What generic launch scenarios exist for Vivotif?
Three scenarios are most relevant.
Scenario 1: No direct competitor
Vivotif remains a differentiated oral option, with competition coming mainly from injectable Vi vaccines and conjugate vaccines. This is the most likely near-term structure if no developer commits to a Ty21a-equivalent product.
Scenario 2: Independent competing oral vaccine
A competitor develops a different oral typhoid vaccine or an alternative attenuated strain. Such a product could compete clinically without relying on Vivotif’s exact formulation. Development timelines, manufacturing validation and market size would limit the probability of rapid entry.
Scenario 3: Direct follow-on Ty21a product
A direct follow-on would face manufacturing, regulatory and commercial barriers. It could affect price in large travel markets, but substitution would not necessarily be automatic because Vivotif is prescribed and dispensed through specialized channels.
The largest practical threat is not a classic generic launch. It is gradual share loss to single-dose injectable vaccines and typhoid conjugate vaccines.
What are the main revenue risks and growth opportunities?
Revenue risks include:
- Declines in international travel.
- Travel restrictions or regional security events.
- Missed doses in the four-capsule regimen.
- Increased use of conjugate vaccines.
- Supply interruptions or cold-chain failures.
- Limited insurance reimbursement.
- Reduced travel-clinic activity.
- Public preference for single-dose vaccination.
Growth opportunities include:
- Continued recovery in international travel.
- Expansion through pharmacies and digital travel-health services.
- Bundling with Vaxchora and other travel vaccines.
- Improved adherence education and reminder systems.
- Use in occupational travelers and humanitarian workers.
- Selective expansion in markets with strong outbound travel.
- Commercial partnerships with travel agencies, employers and travel clinics.
Vivotif’s revenue trajectory should therefore be modeled as a mature, seasonal travel-vaccine business with moderate recovery and portfolio value, not as a high-growth biologic driven by new indications.
Key Takeaways
- Vivotif is a live oral Ty21a typhoid vaccine owned by Bavarian Nordic after its acquisition from Emergent BioSolutions.
- Standalone Vivotif revenue is not publicly disclosed; reported financial data cover broader travel-health activities.
- Financial performance is tied closely to international travel, travel-clinic utilization and seasonal demand.
- Vivotif competes with Vi polysaccharide vaccines and typhoid conjugate vaccines, with the strongest differentiation coming from oral administration.
- Its original patent position is mature, and no major current Orange Book, Paragraph IV or biosimilar event defines the product’s market.
- Manufacturing know-how, regulatory history, cold-chain capability and commercial distribution are more important barriers than remaining patent exclusivity.
- The main long-term competitive risk is substitution by single-dose injectable and conjugate vaccines rather than a conventional generic launch.
- Bavarian Nordic’s acquisition gives Vivotif portfolio and channel value, but the product remains exposed to travel-market volatility.
FAQs
Is Vivotif a biologic drug or a vaccine?
Vivotif is a biologic vaccine. It contains a live attenuated strain of Salmonella Typhi and is regulated as a biological product rather than as a conventional small-molecule drug.
How long does Vivotif protection last?
Protection is generally maintained for approximately five years in individuals who remain at risk, after which revaccination may be recommended. Duration varies by exposure risk and official public-health guidance.
Can Vivotif be replaced by a single injection?
Yes. Injectable Vi polysaccharide and typhoid conjugate vaccines are alternatives, but they differ in age eligibility, duration of protection, dosing and regulatory availability.
Is Vivotif covered by insurance?
Coverage varies by country, insurer and travel indication. In the United States, travel vaccines are often paid out of pocket, so reimbursement should not be assumed.
Does Vivotif have a large remaining patent moat?
No large remaining patent moat is evident from the product’s age and public commercial history. Its practical protection comes from regulatory approvals, manufacturing expertise, product quality, distribution and brand familiarity.
References
-
U.S. Food and Drug Administration. (2021). Vivotif: Typhoid vaccine live oral Ty21a prescribing information. FDA.
-
Centers for Disease Control and Prevention. (2024). Typhoid and paratyphoid fever: Yellow Book. CDC.
-
Bavarian Nordic. (2023). Bavarian Nordic completes acquisition of travel health business from Emergent BioSolutions. Bavarian Nordic A/S.
-
World Health Organization. (2018). Typhoid vaccines: WHO position paper, March 2018. Weekly Epidemiological Record, 93(13), 153-172.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
